Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.46 |
| ▸ | PDE4A | P27815 | 13/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.46 |
| ▸ | PDE5A | O76074 | 11/20 | 0.44 |
| ▸ | PDE1A | P54750 | 10/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 10/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747490 | 0.89 | PDE4A (0.40) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7288680 | 0.88 | PDE3B (0.49) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7286296 | 0.84 | PDE3B (0.55) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7276796 | 0.79 | PDE4A (0.57) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7276791 | 0.79 | PDE3B (0.51) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7286791 | 0.79 | PDE3B (0.47) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7279466 | 0.79 | PDE3B (0.49) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7285560 | 0.78 | PDE3B (0.52) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7278945 | 0.78 | PDE3B (0.48) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7279090 | 0.76 | HSD17B10 (0.41) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550475-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550476-B2 | Condensed polycyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| US-7550464-B2 | Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis | MITSUBISHI TANBE PHARMA CORPORATION (JP) | 2009-06-23 | — | — | US | disclosed |
| EP-1424326-B1 | FUSED-POLYCYCLIC COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070010521-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070004739-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004740-A1 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7153859-B2 | Condensed polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20040204418-A1 | Fused-polycyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1424326-A1 | FUSED-POLYCYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6214996-B1 | SHOWING EXCELLENT BRONCHIOCONSTRICTION INHIBITORY ACTIVITY,USEFUL IN THE PROPHYLAXIS OR TREATNEBT OF ASTHMA | TANABE SEIYAKU CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6005106-A | BRONCHOCONSTRICTOR AGENTS USEFUL IN THE TREATMENT OF ASTHMA | TANABE SEIYAKU CO., LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5969140-A | AMINOPYRIDINE DERIVATIVES OF NAPHTHALENE FOR TREATMENT OF ASTHMA AND BRONCHOCONSTRICTOR INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0748805-B1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0748805-A1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0557016-B1 | Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor | TANABE SEIYAKU CO (JP) | 1996-06-19 | — | — | EP | disclosed |
| US-5342941-A | Bronchodilating agents | TANABE SEIYAKU CO., LTD. (JP) | 1994-08-30 | — | — | US | disclosed |
| EP-0557016-A1 | Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor | TANABE SEIYAKU CO., LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004740-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | PDE3B 3/4885PDE3A 5/4885PDE4A 1/4885 |
| US-20070010521-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | PDE3B 3/4885PDE3A 5/4885PDE4A 1/4885 |
| US-20070004739-A1 | Condensed polycyclic compounds | PDE4A, PDE4B, PDE3B | PDE3B 3/4885PDE3A 5/4885PDE4A 1/4885 |
| US-20040204418-A1 | Fused-polycyclic compounds | PDE4A, PDE4B, PDE3B | PDE3B 3/4885PDE3A 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.